Background {#S0001}
==========

Globally, tuberculosis (TB) becomes a public health concern due to the emerging drug-resistant tuberculosis.[@CIT0001],[@CIT0002] It is the second cause of mortality after malaria, the third cause of hospital admissions, and the main reason for morbidity in Ethiopia.[@CIT0003]

TB is the most common infectious disease in the pediatric population.[@CIT0004] Less than half of the estimated 1 million children sick from TB were diagnosed and reported to the World Health Organization (WHO) in 2018.[@CIT0005],[@CIT0006] An estimated 230,000 children died of TB, among which 80% were younger than five years old. Ninety-six percent of child deaths from TB occur before the treatment is ever started.[@CIT0007]

Among the world's 22 high-burden TB countries, Ethiopia ranked seventh. Approximately one million children are estimated to be infected by TB worldwide of which three fourth of them were found in the 22 high-burden countries including Ethiopia.[@CIT0005] Therefore, to decrease the disease prevalence, compressive intervention should be undertaken by different responsible organizations and stakeholders.[@CIT0008]

Adherence among Pediatrics TB patients is complex which is affected by the patients themselves and the health care system.[@CIT0009] Non-adherences to TB treatment can increase TB prevalence and multi-drug resistant tuberculosis (MDR-TB) that in turn increases morbidity and mortality.[@CIT0003],[@CIT0010]-[@CIT0012] Mortality from MDR-TB and extensively drug-resistant TB (XDR TB) groups was 4.4% and 9.3%, respectively.[@CIT0013]

Concurrent human immune virus (HIV) and TB infection can increase the complexity of TB therapy and it is estimated that 50%of TB patients are co-infected with HIV.[@CIT0014] Both diseases place a big social, economic, and health burden. Patients with HIV and TB are likely to face more challenges because they have to get HIV care in addition to TB care. Because of their immune suppression, patients are more likely to get severe forms of TB.[@CIT0015],[@CIT0016]

Non-adherence to tuberculosis treatment is the most challenging and hindering factor for successful tuberculosis therapy. Directly Observed Therapy (DOT) is introduced to ensure patient's adherence to the treatment by giving every dose under direct observation and has been related to decreased rate of treatment failure, relapse and drug resistance. Despite this, its influence on decreasing TB incidence has been inadequate which happens when patients do not turn-up for treatment at the health facility.[@CIT0003],[@CIT0016]-[@CIT0020]

Despite poor TB treatment outcomes of pediatric patients, few studies were reported regarding adherence in Africa.[@CIT0009] Longer duration of anti TB drugs and their safety may add a particular challenge for non-adherence. However, individualized regimens for drug-resistant TB may help to overcome side effects and increase treatment success.[@CIT0014],[@CIT0019],[@CIT0021] Anti-TB treatment among pediatric patients is challenging due to a lack of pediatrics drug formulations and difficulties in monitoring drug toxicity. Unlike adults, all children should be treated for latent TB infection if identified.[@CIT0022]

Adherence to long term treatment is crucial to TB control. A comprehensive approach to TB determinants and enhanced disease awareness may increase treatment adherence.[@CIT0004],[@CIT0014],[@CIT0018] Studying risk factors for non-adherence is also playing a paramount role to avoid MDR-TB.[@CIT0019] Determining the contributing factors for non- adherence is indispensable to reduce the TB disease burden and poor outcomes. Hence, this study was aimed to evaluate pediatrics adherence status among tuberculosis pediatric patients on anti-tuberculosis treatment at Nekemte Specialized Hospital.

Patients and Methods {#S0002}
====================

Study Setting, Design and Study Period {#S0002-S2001}
--------------------------------------

A health facility-based cross-sectional study design was used to determine the level of adherence to anti-TB treatment among pediatric TB patients on follow up from February 15 to March 15, 2019 at Nekemte Specialized Hospital (NSH). NSH is found in Nekemte town, which is located 330 km to the west of Addis Ababa, the capital city of Ethiopia. The hospital is a specialized hospital and gives health services for more than 10 million people living in western Ethiopia.

Study Participants and Eligibility Criteria {#S0002-S2002}
-------------------------------------------

Pediatric TB patients ≤15 years old who were on anti-TB treatment for at least 1 month and whose caregivers consented to participate in the study were included in the study. Patients who had transferred out to another health facility after treatment started and pediatric TB patients with incomplete data were excluded from the study.

Study Variables and Outcome Endpoints {#S0002-S2003}
-------------------------------------

The primary outcome variable was adherence to anti-TB treatment whereas independent variables include socio-demographic factors (age, sex, weight, area of residence) and drug-related factors (treatment duration, prescribed medications other than anti-tuberculosis, previous exposure of side effect). The adherence to the drug was assessed based on the self-report of the caregivers. The proportion of adherence was calculated as the number of doses taken by the patients as prescribed by the clinician divided by the number of doses prescribed to the patients in the last 30 days. To calculate the percentage of adherence the ratio was multiplied by 100. Patients who took ≥90% of their medication as prescribed were said to be adherent whereas \< 90% were considered as non-adherents.[@CIT0019]

Sample Size Determination and Sampling Technique {#S0002-S2004}
------------------------------------------------

A total of 231 pediatric TB patients were receiving treatment at NSH from February 15 to March 15, 2019. But 202 Pediatric TB patients' fulfilling the inclusion criteria were included in the final analysis. Hence, the study participants were selected using a convenience sampling technique.

Data Collection Process and Management {#S0002-S2005}
--------------------------------------

Data were collected using a semi-structured data collection tool which was developed after reviewing different previous pieces of literatures.[@CIT0009],[@CIT0011],[@CIT0012],[@CIT0023]-[@CIT0025] The data collection tool was translated to the area's local language (Afan Oromo and Amharic) and back-translated to English to ensure consistency of meaning. Data were collected by face-to-face interviews of the caregivers of the Pediatric Tb patients. Three nurses and two pharmacists who were working in the TB clinic were selected as data collectors. During the data collection, the completed questionnaires were reviewed and checked for completeness, accuracy, and consistency. Five percent of the sample was pre-tested at Wollega university referral hospital to check the consistency of the data collection tool before data collection was commenced.

Data Processing and Analysis {#S0002-S2006}
----------------------------

EPI-manager 4.0.2 software was used to enter data and analysis was done using statistical software for social sciences (SPSS) version 24. Descriptive data were explained by proportion, means and standard deviations (SD). Multivariable logistic regression was used to analyze the variable and each variable was evaluated independently in bivariate analysis and association was determined using cross-tabulation and crude odds ratio (COR) with 95% confidence interval (CI). All variables that had p-value of less than or equal to 0.25 on the bivariate analysis were entered into multivariate logistic regression. Adjusted odds ratios (AOR) with 95% confidence intervals were computed and the variables with p-value of less than or equal to 0.05 had a statistically significant association with the adherence to anti TB treatment.

Operational Definitions {#S0002-S2007}
-----------------------

Pediatrics: Children whose ages were ≤ 15 years.

Adherent: Patients who took \> 90% of their expected medication doses.[@CIT0003],[@CIT0019]

Non- adherent: Patients were considered non-adherent to treatment if they took \< 90% of their expected medication doses.[@CIT0003],[@CIT0019]

Results {#S0003}
=======

Socio-Demographic Characteristics of Study Participants {#S0003-S2001}
-------------------------------------------------------

Among 202 patients involved in the study, 120 (59.4%) of them were males and 119 (58.9%) were in the age category of 11--15 years. Regarding the weight of the participants, about 148 (73.3%) of them were more than 25kg weight and the majority of participants 126 (62.4%) were from rural residences ([Table 1](#T0001){ref-type="table"}).Table 1Socio-Demographic Characteristic of the Pediatrics TB Patients Attending NSH, 2019VariablesFrequency (n)Percent (%)Age (years)0--54321.36--104019.811--1511958.9GenderMale12059.4Female8240.6Weight (kg)\<255426.7≥2514873.3ResidenceUrban7637.6Rural12662.4

Disease and Clinical Related Characteristics {#S0003-S2002}
--------------------------------------------

The majority of 166 (82.2%) the patients had extra-pulmonary TB and 192 (95%) of them were HIV negative. Regarding the treatment phase, 174 (86.1%) of them were in the intensive phase. Almost all of the patients who were in the intensive phase were taking two medications consisting of isoniazid and rifampin. About 126 (62.4%) of the study participants had experienced TB treatment-related side effects, of those the commonest reported were nausea, vomiting and diarrhea comprising of 55 (27.2%). A total of 15 (7.4%) of the participants reported as they were taking other medication besides TB treatment and of those taking additional treatment, about 10 (5.0%) were taking Highly Active Anti-Retroviral Therapy HAART regimen of Zidovudine + Lamivudine+ Efavirenz ([Table 2](#T0002){ref-type="table"}).Table 2Disease and Clinical Related Characteristics of TB Pediatrics Patients Attending NSH, 2019VariablesFrequency (n)Percent (%)Side effectYes12662.4No7637.6Type of side effect (n=126)NVD5527.2Changed eye color2713.4Other4421.8Disease classificationPTB-SM+2411.9PTB-SM-125.9EPTB16682.2Pre-treatment Smear resultSmear positive6431.7Smear negative178.4Not done12159.9Treatment phaseIntensive17486.1Continuous2813.9HIV statusPositive105Negative19295Medicines besides TB treatmentYes157.4No18792.6Total202100Medicine was taking for (n=15)HAART1066.7Multivitamins533.3[^1]

TB Treatment Adherence {#S0003-S2003}
----------------------

About 148 (73.3%) of them had adhered to their treatment regimen, and the rest 54 (26.7%) had not adhered to their anti-TB drugs.

Association Between TB Treatment Adherence Level and Related Factors {#S0003-S2004}
--------------------------------------------------------------------

In bivariate analysis, age, sex, weight, residence, treatment duration, taking other medication besides TB treatment and side effect experiences were associated with TB treatment adherence at p-value ≤0.25.

However, in the multivariate analysis age, sex, residence, and side effect experience showed an association with TB treatment adherence at p-value \<0.05. In this study, patients who were in the age category of 0--5 years were about 6 times more likely to adhere to TB treatment than those in the age category of 11--15 years (AOR: 5.96 95% CI:1.81--19.6). Female patients were 3.3 times more likely to adhere to TB treatment than males (AOR: 3.3, 95% CI: 1.52--7.2). Patients from urban settings were 3.73 times more likely to adhere to TB treatment compared to rural residents. (AOR: 3.73, 95% CI: 1.67--8.36). Finally, patients who did not experience side effects were 2.87 times more likely to adhere to their TB treatment than those who experienced any side effects (AOR: 2.87, 95% CI: 1.41--5.81) ([Table 3](#T0003){ref-type="table"}).Table 3Bivariate and Multivariate Analysis of Factors Associated with TB Treatment Adherence Among Pediatrics Patients Attending NSH, 2019VariablesAdheredNot AdheredCOR (95% CI)AOR (95% CI)p-valueAge (age)0--539 (90.7%)4 (9.3%)4.94 (1.65--14.78)\*5.96 (1.81--19.6)\*\*0.0036--1030 (75%)10 (25%)1.52 (0.67--3.42)1.75 (0.7--4.36)0.2311--1579 (66.4%)40 (33.6%)11SexMale81 (67.5%)39 (32.5%)11Female67 (81.7%)15 (18.3%)2.15 (1.09--4.24)\*3.3 (1.52--7.2)\*\*0.003Weight (kg)≥2545 (83.3%)9 (16.7%)2.18 (0.98--4.85)\*0.74 (0.19--2.84)0.6\<25103 (69.6%)45 (30.4%)11ResidenceUrban52 (68.4%)24 (31.6%)3.29 (0.78--2.78)\*3.73 (1.67--8.36)\*\*0.001Rural50 (39.7%)76 (60.3%)11Treatment duration (months)≤2130 (74.7%)44 (25.3%)1.64 (0.7--3.82)\*\>218 (64.3%)10 (35.7%)1Treatment phaseIntensive114 (91.2%)60 (77.9%)2.94 (0.93--8.24)Continuous11 (7.3%)17 (22.1%)1Taking other medicationYes10 (66.7%)5 (33.3%)1No138 (73.8%)49 (26.2%)1.41 (0.46--4.32)\*Experienced side effectsYes81 (81%)45 (19%)1No46 (60.5%)30 (39.5%)2.76 (1.46--5.25)\*2.87 (1.41--5.81)\*\*0.013[^2][^3]

Discussion {#S0004}
==========

Drug resistance and treatment failure may happen as a result of non-adherence to anti-TB treatment.[@CIT0012] Thus, the finding of this study plays a paramount role in achieving the TB treatment success rate by decreasing the occurrences of drug resistance.

The study revealed that the overall treatment adherence level was 73.3%, which was higher than study in north Portugal (63.9%)[@CIT0004] and Mozambique (68.7%),[@CIT0009] but lower than a systematic review and meta-analysis conducted by Zegeye et al (78.71%).[@CIT0003] The differences in different findings could be due to variations in definitions of anti-TB non-adherence. No gold standard definition of adherence towards ant-TB treatment is yet available although quantity and timing of missed medication or hospital appointments were recommended by WHO. In our study, patients who missed 10% or more of their prescribed doses of anti-TB drugs were considered as non-adherents while others measured non-adherence if patients discontinued medication for 6 days.[@CIT0026]

According to two African studies, younger age was associated with non-adherence.[@CIT0027],[@CIT0028] On the contrary, in our study younger ages (0--5 years) were 5.96 times more likely to adhere to TB treatment than those in older ages (11--15 years). In our setting, pediatric populations did not face significant problems during TB treatment in comparison to the older age due to more support from their social network and caregivers. Hence, pediatric patients took their medication under the supervision of their family that increases the adherence level.

We found differences in adherence to anti-TB therapy between gender. Female patients were 3.3 times more likely to adhere to TB treatment than males. This finding was consistent with the study done in Argentina.[@CIT0023] This might be because most females stay at home compared to males who are always busy with playing with their peers. Hence, females have less chance of missing their medications. However, the finding was different from the study done in Uganda, and Mozambique that revealed there was no significant difference between genders related to adherence status.[@CIT0009],[@CIT0014]

Patients from urban were 3.73 times more likely adhere to TB treatment compared to rural residents. This was inconsistent with the finding at Alamata District, Northeast Ethiopia in which the adherence rate was similar among urban and rural residents.[@CIT0001] Patients' lives in urban areas are more aware of the disease and easily access to nearby health facilities to deal with their treatments. Besides this, patients from rural areas miss their appointment due to low level of knowledge, lack of transportation, and other facilities.

Patients who did not experience side effects were 2.87 times more likely to adhere to TB treatment than those who experienced any side effects. This was consistent with the study conducted in Southern Ethiopia and Northern Ethiopia, in which side effects of the drugs is an important reason for non-adherence to anti TB drugs.[@CIT0021],[@CIT0029] On the contrary, the study conducted in Uganda revealed that adverse effects did not have an association with non-adherence.[@CIT0014] This might be due to clinical pharmacy service has fully applied in that area. When patients experience any side effects, they are fear taking their medications and develop a negative attitude toward the medications. If they are not convinced of the positive consequence of their medication, they start to interrupt to take the medications. Hence, during the provision of the medication and educating patients regarding common side effects helps to improve the adherence level.

Strength and Limitations of the Study {#S0005}
=====================================

As a strength, we tried to assess the level of TB treatment adherence in both pulmonary and extra-pulmonary TB patients who received their treatment in the study area. As a limitation, adherence was assessed based on retrospective data with incomplete information. Additionally, since it was a cross-sectional study, it is difficult to predict causality. We were also unable to assess all non-adherence risk factors investigated by other studies (like long wait times in the healthcare facility, distance from the health facility, cost of medications, forgetfulness, the use of herbal medication, social drug use, and co-infection with HIV) since that was operationally difficult at the time of data collection. Lastly, there might be a bias due to a self-reported assessment and was not recorded in any manner via a visual analog scale. Hence caution should be given to generalizing the finding for a large community.

Conclusion {#S0006}
==========

Compared to the previous studies, the level of adherence observed in our study area was low. Therefore, health care providers should educate all TB patients before the initiation of treatment focusing on the duration of treatment using locally used language. Additionally, clinical pharmacist plays a pivotal role in counseling the patients towards possible side effects of anti TB drugs and ways of management. Furthermore, strengthening facility DOT for patients staying close to the health facility is needed. This would enable as many patients as possible to be observed by the health care professional when taking their drugs. For the patients living in rural areas, bringing the services closer to where they live is paramount in increasing their adherence status.
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[^1]: **Abbreviations:** HAART, highly active ant-retroviral therapy; NVD, nausea, vomiting, and diarrhea; EPTB, extrapulmonary tuberculosis; PTB-SM+, smear positive pulmonary tuberculosis; PTB-SM-, smear negative pulmonary tuberculosis.
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